PART I Overview We are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope. Objectives and Business Strategy Our le...
Q2 FY2026 — expected 2026-07-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001493152-26-010102 | EDGAR | 72K words |
| 2025-03-12 | 2024-12-31 | 0001493152-25-010051 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0001140361-24-013254 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0001140361-23-012418 | EDGAR | — |
| 2022-04-15 | 2021-12-31 | 0001140361-22-014764 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001493152-21-005827 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001493152-20-004343 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001493152-19-003770 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001493152-18-003164 | EDGAR | — |
| 2017-03-09 | 2016-12-31 | 0001493152-17-002280 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001493152-25-021287 | EDGAR | 24K words |
| 2025-08-13 | 2025-06-30 | 0001493152-25-011910 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001641172-25-009044 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044841 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001493152-24-031639 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001140361-24-026010 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001140361-23-052742 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001140361-23-039283 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001140361-23-024180 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001140361-22-041399 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001140361-22-029251 | EDGAR | — |
| 2022-07-01 | 2022-03-31 | 0001140361-22-024669 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001493152-26-011922 | EDGAR | 1K words |
| 2026-02-26 | 0001493152-26-008182 | EDGAR | — |
| 2026-02-11 | 0001493152-26-006227 | EDGAR | — |
| 2025-12-11 | 0001493152-25-027167 | EDGAR | — |
| 2025-07-07 | 0001641172-25-018009 | EDGAR | — |
| 2025-06-12 | 0001641172-25-014877 | EDGAR | — |
| 2025-06-09 | 0001641172-25-014318 | EDGAR | — |
| 2025-06-02 | 0001641172-25-013249 | EDGAR | — |
| 2025-04-03 | 0001641172-25-002514 | EDGAR | — |
| 2025-03-26 | 0001641172-25-000681 | EDGAR | — |
371 total filings indexed. 339 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000748592 |
| Ticker | ERNA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ernexatx.com |
| Listed | 2021-03-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report